跳至主要内容
临床试验/NCT07585032
NCT07585032招募中不适用

Safety and Efficacy of EUS-RFA in Pancreatic Insulinoma

Sahlgrenska University Hospital1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2025年3月31日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
20
试验地点
1

研究概览

简要总结

Transcutaneous and EUS-guided radiofrequency ablation are both modern modalities to apply in the managemnet of various malignancies.

In the current study the investigators aim to study the technical feasibility, patient safety and clinical efficacy of EUS-RFA for the treatment of pancreatic insulinoma.

详细描述

Patients (P): Alla patients referred to Sahlgrenska University Hospital for the diagnostic work-up and management of a suspected pancreatic insulinoma.

Intervention (I): EUS-RFA

Control group (C): Patients with insulinoma treated with conventional surgery during the time frame 2018-2025 (historic controls).

Outcome (O):

  • Technical feasibility
  • Patient safety
  • Clinical efficacy (follow-up with biochemistry and imaging at 3, 6, 12, and 24 months post-EUS-RFA).

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
15 Years 至 80 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Insulinoma verified by pathology (often from EUS-FNB-sampling)

排除标准

  • Patients unwilling to participate
  • Patients unable to understand and obtain written informed conscent
  • Severe comorbidity

研究者

发起方
Sahlgrenska University Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Per Hedenström

Senior Consultant

Sahlgrenska University Hospital

研究点 (1)

Loading locations...

相似试验